Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: Shares of the company traded marginally down at $132.47, after having closed up 1.7% on Monday. (bit.ly/2ZkZGze)    J&J said that the FTC had issued a “civil investigative demand,” or CID, the equivalent of a subpoena to determine if the contracting practices were legal. Pfizer Inc filed a lawsuit against J&J in 2017, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and aimed at blocking sales of Pfizer’s biosimilar called Inflectra. Pfizer said in the lawsuit that J&J had contracted with many insurers to give discounts in exchange for giving preference to Remicade, and to only pay for Inflectra in cases where Remicade proved to be ineffective. Inflectra was approved in 2016 while Remicade went on the market in 1998. Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the lawsuit. J&J has denied any wrongdoing and is fighting the Pfizer lawsuit. Pfizer said in a statement that it had received a CID in June. “As Pfizer’s complaint alleges, J&J’s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation – price. Today, Inflectra has an average selling price (ASP) that is more than 22% lower than Remicade,” the company said in a statement. “Despite these facts, J&J has not lost substantial volume or share of sales – counter to what should occur in a competitive market.”  Biosimilars are intended to be lower-cost alternatives to expensive biotech medicines. But since they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be. The drugs treat ailments like rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Claim: J&J says FTC probing efforts to protect arthritis drug Remicade.
[A]: The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.


[Q]: Paragraph: The Douglas County Health Department said Wednesday that the bat was found on the ground at Morton Middle School on Friday afternoon. The bat was sent to a state lab and tested positive for the infectious disease. A small group of students at the school were seen around the bat, and officials are urging anyone who had any physical contact with the bat to contact their doctor as soon as possible. Rabies is a viral disease transmitted through the bite or scratch of an infected animal that affects people. It is almost always fatal if not treated before symptoms appear. Claim: Officials warn of exposure to rabid bat at Omaha school.
[A]: Health officials in Omaha are notifying parents that some students at a city middle school may have been exposed to a rabid bat was found on school grounds.


[Q]: Paragraph: The Maine Center for Disease Control says the state has had 51 acute cases in 2019 and is running a rate nearly three times the national average. Director of the Maine CDC, Dr. Nirav Shah, says the cases of hepatitis C in Maine is “an unfortunate outcropping of the substance use crisis.” Executive director of the Health Equity Alliance, Kenney Miller, says the long-term goal’s to have at least one syringe exchange in all 16 counties. The Portland Press Herald reports there are currently exchange programs in Bangor, Ellsworth, Belfast, Machias, Portland, Augusta and Waterville. Shah says increasing the number of exchanges is one of the top priorities of the Mills administration. ___ This story has been corrected to show there are 51 cases of acute hepatitis C diagnosed in Maine this year, not 59. Claim: Maine plans to expand syringe exchange program.
[A]:
Maine plans to launch a $1.5 expansion of syringe exchanges to combat the surge in hepatitis C cases in the state.